H.C. Wainwright has assumed coverage of DURECT (NASDAQ:DRRX) with a “buy” rating and $3 price target. The stock was quoted at $1.02 in afternoon trading on Feb. 28.Read More
Maxim Group initiated coverage of Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a “buy” rating and 12-month price target of $32. The stock closed at $22.10 on Feb. 23.Read More
The U.S. Patent and Trademark Office has issued a patent term adjustment (PTA) extending the patent term by 18 months for Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent titled, “Methods and Compositions for Oral Administration of Proteins.”
Oramed had previously received an allowance on the patent. The PTA increases the patent term from the standard 20 years to 21 years and six months, extending the term through March 2028.Read More
Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office.
Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule, ORMD-0801. Having completed multiple Phase 2a trials, a Phase 2b trial in patients with Type 2 diabetes is ongoing under an IND with the FDA. In addition Oramed is developing an oral GLP-1 analog capsule, ORMD-0901.Read More
H.C. Wainwright analyst, Ed Arce, has assumed coverage of Galmed Pharmaceuticals (NASDAQ:GLMD) with a “buy” rating and $22 price target. The stock closed at $4.44 on Friday.
Galmed is focused on the development of a sole drug candidate, aramchol, as a potentially disease-modifying treatment for nonalcoholic steatohepatitis (NASH).Read More